BridgeBio Pharma Inc (BBIO) - Total Assets
Based on the latest financial reports, BridgeBio Pharma Inc (BBIO) holds total assets worth $998.25 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BridgeBio Pharma Inc - Total Assets Trend (2017–2024)
This chart illustrates how BridgeBio Pharma Inc's total assets have evolved over time, based on quarterly financial data. Also see BBIO market cap for the company's overall valuation and market capitalisation.
BridgeBio Pharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
BridgeBio Pharma Inc's total assets of $998.25 Million consist of 78.4% current assets and 21.6% non-current assets. Review BridgeBio Pharma Inc (BBIO) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.1% |
| Accounts Receivable | $4.72 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $23.93 Million | 2.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how BridgeBio Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest BridgeBio Pharma Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BridgeBio Pharma Inc's current assets represent 78.4% of total assets in 2024, a decrease from 99.1% in 2017.
- Cash Position: Cash and equivalents constituted 74.1% of total assets in 2024, down from 93.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 2.6% of total assets.
BridgeBio Pharma Inc Competitors by Total Assets
Key competitors of BridgeBio Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
BridgeBio Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.88 | 3.19 | 6.72 |
| Quick Ratio | 3.76 | 3.19 | 6.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $622.78 Million | $305.36 Million | $547.18 Million |
BridgeBio Pharma Inc - Advanced Valuation Insights
This section examines the relationship between BridgeBio Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 123.68 |
| Latest Market Cap to Assets Ratio | 14.24 |
| Asset Growth Rate (YoY) | 68.3% |
| Total Assets | $919.34 Million |
| Market Capitalization | $13.09 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values BridgeBio Pharma Inc's assets at a significant premium (14.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: BridgeBio Pharma Inc's assets grew by 68.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BridgeBio Pharma Inc (2017–2024)
The table below shows the annual total assets of BridgeBio Pharma Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $919.34 Million | +68.26% |
| 2023-12-31 | $546.38 Million | -12.30% |
| 2022-12-31 | $623.04 Million | -38.48% |
| 2021-12-31 | $1.01 Billion | +43.95% |
| 2020-12-31 | $703.59 Million | +11.38% |
| 2019-12-31 | $631.68 Million | +35.86% |
| 2018-12-31 | $464.94 Million | +374.22% |
| 2017-12-31 | $98.04 Million | -- |
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM);… Read more